METHODS	We performed a prospectively randomized phase III study comparing carboplatin-paclitaxel ( TC ; area under the curve 5/175 mg/m2 , respectively ) with epirubicin 60 mg/m2 added to the same combination ( TEC ) in previously untreated patients with advanced epithelial ovarian cancer .\